Comparative analysis of breast cancer contamination in mobilized and nonmobilized hematopoietic grafts

Journal of Hematotherapy and Stem Cell Research

Volumn 5, Issue 5, 1996, Pages 549-552

  Ross, A A ^a   Layton, T J ^a   Ostrander, A B ^a   Passos Coelho, J L ^b   Davis, J M ^b   Huelskamp, A M ^b   Noga, S J ^b   Davidson, N E ^b   Kennedy, M J ^b   Cooper, B W ^c   Gerson, S L ^c   Lazarus, H M ^c   Holland, K ^d   Gluck, S ^e   Moss, T J ^f   Kaubish, A ^g   Vahdat, L ^g   Antman, K ^g  

^a Cell Pro Inc   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d EMORY UNIVERSITY   (United States)

^e NE Ontario Regional Cancer Center ^*  (Canada)

^f CHILDREN S HOSPITAL LOS ANGELES   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

APHERESIS; ARTICLE; BONE MARROW; BREAST CANCER; CANCER RECURRENCE; IMMUNOCYTOCHEMISTRY; METASTASIS; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

BREAST NEOPLASMS; CELL SEPARATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; NEOPLASM, RESIDUAL;

EID: 0029959496     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.1.1996.5.549     Document Type: Review

References (12)

1. Sharp, J.G., Kessinger, A., Vaughan, W.P., et al. Detection and clinical significance of minimal tumor contamination of peripheral stem cell harvests. Int. J. Cell Cloning 10(Suppl. 1):92, 1992.
2. Ross, A.A., Cooper, B.W., Lazarus, H.M., et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82:2605, 1993.
3. Shpall, E.J., Jones, R.B., Bearman, S.I., et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral blood progenitors and growth factors on engraftment. J. Clin. Oncol. 12:28, 1994.
4. Ross, A.A., Loudovaris, M., Hazelton, B., et al. Immunocytochemical analysis of tumor cells in pre- and post-culture peripheral blood progenitor cell collections from breast cancer patients. Exp. Hematol. 23:1480, 1995.
5. Passos-Coelho, J.L., Ross, A.A., Davis, J., et al. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: Effect of ex vivo purging with 4-hydroperoxycyclophosphamide. Cancer Res. 54:2366, 1994.
6. Ross, A.A., Farmer, S.L., Moss, T.J., et al. Tumor contamination of peripheral blood stem cell collections from breast cancer patients: Influence of clinical status at time of pheresis. Breast Cancer Res. Treat. 32 (Suppl.):63a, 1994.
7. Moss, T.J., Cairo, M.S. Bostrom, B., et al. Using bone marrow immunocytochemical analysis to determine optimal timing of peripheral blood stem cell harvest for patients with breast cancer and neuroblastoma. Blood 84 (Suppl. 1):354a, 1994.
8. Brugger, W., Bross, K.J., Glatt, M., et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83:636, 1994.
9. Passos-Coelho, J.L., Ross, A.A., Moss, T.J., et al. Absence of breast cancer cell mobilization into peripheral blood progenitor cell collections by priming with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 85:1138, 1995.
10. Passos-Coelho, J.L., Ross, A.A., Moss, T.J., et al. Low incidence of breast cancer contamination of a single peripheral blood progenitor cell collection after priming with hematopoietic cytokine alone or cytokine and cyclophosphamide. Proc. Am. Soc. Clin. Oncol. 14:313a, 1995.
11. Ybanez, J., Lazarus, H.M., Ross, A.A., et al. Impact of occult tumor reinfusion on outcome after high-dose chemotherapy in patients with advanced breast cancer. Blood 86:386a, 1995.
12. Peters, W.P., Berry, D., Vredenburgh, J.J., et al. Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving ≥10 axillary lymph nodes. Proc. Am. Soc. Clin. Oncol. 14:317a, 1995.